Drugs / ABP1011T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07321574 | Dec 2025 → Nov 2028 expected | small cell lung carcinoma | Shanghai AB PharmaTech Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABP1011T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07321574 ↗ |
| Route | Oral | “Participants take one tablet orally once daily” NCT07321574 ↗ |